CASE REPORT

Glue for Sealing Internal Pancreatic Fistula in a Patient with Liver Cirrhosis: A Useful Technique

Mahesh Kumar Goenka, Ashish Kumar Jha, Nisha Kapoor, Usha Goenka

Institute of Gastro Sciences, Apollo Gleneagles Hospital. Kolkata, India

ABSTRACT

Context Pancreatic fistulae are uncommon and usually follow acute or chronic pancreatitis. While most of these are treated conservatively, some require surgery. Recently endoscopic therapy has emerged as an effective alternative treatment modality. Case report We present a patient with internal pancreatic fistula due to alcohol related chronic pancreatitis. Endotherapy using glue resulted in resolution of the fistula. Conclusion The use of endoscopic glue injection may be a safe and effective method for the successful therapy of internal pancreatic fistula.

INTRODUCTION

Pancreatic fistulae are uncommon but grave complication of acute or chronic pancreatitis. They may also occur following abdominal surgery or trauma. Internal pancreatic fistulae are most commonly seen with alcohol related chronic pancreatitis and can involve any part of the pancreatic duct [1]. Reported incidence of pancreatic fistula varies widely because of the use of different definition/criteria in these studies. Bragg et al. reported an incidence of pancreatic fistula in 2% of patients with acute pancreatitis [2]. Chebli et al. found that an internal pancreatic fistula occurs in 7.3% of patients having chronic pancreatitis [3]. The reported incidence of pancreatic fistula formation following partial pancreaticoduodenectomy, left pancreatectomy and pancreatic trauma are 12.9%, 13.0% and 11.9% respectively [4]. We present a relatively new modality of endoscopic therapy for internal pancreatic fistula.

CASE REPORT

A 59-year-old male presented with painless progressive distension of abdomen of three months duration. He had been consuming 30 g of alcohol daily for the last 20 years. Clinically he was anicteric, afebrile and had tense ascites. The hematological and biochemical investigations revealed hemoglobin of 14.4 g/dL (reference range: 13.0-17.0 g/dL), white blood cell count of 10,500 cells/mm$^3$ (reference range: 4,000-10,000 cells/mm$^3$) (70% polymorphonuclear cells), bilirubin of 0.9 mg/dL (reference range: 0-1 mg/dL), AST of 60 IU/L (reference range: 10-42 IU/L) and ALT of 53 IU/L (reference range: 10-40 IU/L); rest of the blood parameters were normal. Abdominal computed tomography (CT) revealed enlarged caudate and left lobes of liver with relatively smaller right lobe, heterogeneous pancreatic parenchyma, collaterals and marked ascites (Figure 1). Ascites was drained and fluid analysis revealed total leukocyte count of 3,360 cells/mm$^3$ (60% polymorphonuclear cells), amylase of 116,963 IU/L and adenosine deaminase of 7 U/L. Ascitic fluid

Figure 1. CT scan at the level of uncinate process of pancreas showing free fluid, localized fluid collection on left side (arrow) and collaterals around the collection.
cultures were negative. Esophagogastroduodenoscopy showed grade II esophageal varices, small gastric fundal varix and mild portal hypertensive gastropathy. Endoscopic ultrasound (EUS) revealed evidence of chronic pancreatitis and ascites. Diagnosis of internal pancreatic fistula was made and the patient was taken up for endoscopic retrograde cholangiopancreatography (ERCP). Magnetic resonance cholangiopancreatography (MRCP) could have delineated the pancreatic ductal anatomy but not done because of a definite diagnosis of pancreatic ascites due to high fluid amylase in presence of CT scan and EUS evidence of chronic pancreatitis. Pancreatogram revealed a leak from distal part of pancreatic duct (Figure 2). Pancreatic sphincterotomy was done. A cannula was placed next to the fistula, flushed with normal saline and one mL of N-butyl-2-cyanoacrylate glue (Histoacryl®, B. Braun, Tuttlingen, Germany) was injected at the fistula site. Immediately after injection of glue, there was a bit of resistance noted on attempt to withdraw the cannula which was removed with a sharp tug. The check pancreatogram revealed sealed leak (Figure 3). A 7 Fr x 9 cm plastic pancreatic stent was placed in the pancreatic duct. The repeat ascitic fluid amylase was found to be 229 IU/L. He subsequently received low dose of diuretics as well and over the next one week ascites has resolved. His pancreatic stent was removed after 3 weeks and check pancreatogram was normal.

**DISCUSSION**

The management of internal pancreatic fistula conventionally included giving complete rest to the pancreas by keeping the patient nil by mouth, parenteral nutrition and external drainage of fluid, if a large collection is present. Subsequently octreotide was added to the above regimen. This therapy requires prolonged hospital stay of up to 4-6 weeks, is expensive and still shows suboptimum success rate [5].

Endoscopic therapy has added a new armamentarium for managing pancreatic fistulas. The aim of endotherapy is to reduce the intrapancreatic duct pressures. The extensively used endoscopic modalities include sphincterotomy, sphincterotomy with stenting, and nasopancreatic drain placement. Successful resolution of fistula has been noted in approximately 90% cases managed by endotherapy [6, 7, 8, 9, 10]. The idea during stent placement is to generally bridge the fistula site which is however not possible in case of leaks from pancreatic tail area. Moreover, dilatation of ductal strictures and removal of calculi can be performed during endotherapy. Endotherapy may be coupled with external drain for large fluid collection. Endotherapy has also been effective in lowering the morbidity and in-hospital stay. However, endoscopic therapy is less effective in leaks from pancreatic tail and excluded pancreatic duct syndrome.

Seewald et al. reported a case series of 12 patients wherein N-butyl-2-cyanoacrylate was injected into the fistulous tract using a catheter during ERCP. The closure of fistula was seen in 8 out of 12 patients (66.7%). Though one person died, it was unrelated to the procedure [11]. Fischer et al. have shown successful closure of 8 out of 8 patients of postoperative pancreatic fistula with the use of fibrin glue [12]. Advantages of N-butyl-2-cyanoacrylate are that we can monitor the injection by mixing with lipiodol and it is more stable than fibrin glue [11]. Mutignani et al. reported 4 patients in whom Glubran® 2 (General Enterprise Marketing, Viareggio, Lucca, Italy) (N-butyl-2-cyanoacrylate with methacryloxy-sulpholane) was used as the sealant. Closure of fistula was seen in 3 out of 4 cases [13]. In another report, Seewald et al. have shown the closure of pancreatic fistula in 2 patients of acute pancreatitis with the endoscopic application of N-butyl-2-cyanoacrylate [14]. In a recent report, 4 patients with pancreatic fistulas that failed to respond to conservative treatment

![Figure 2. Pancreatogram showing leak (red arrow) from distal pancreatic duct. Note: guide wire (purple arrow).](image2)

![Figure 3. Check pancreatogram showing main pancreatic duct with sealed leak.](image3)
Table 1. Reports of pancreatic fistulae treated with endoscopic glue injection.

<table>
<thead>
<tr>
<th>Reference</th>
<th>Number of cases</th>
<th>Etiology of fistula</th>
<th>Glue used</th>
<th>Success rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seewald S et al. [11]</td>
<td>12</td>
<td>Chronic pancreatitis (4 cases) Acute pancreatitis (3 cases) Postoperative (3 cases) Cancer (2 cases)</td>
<td>N-butyl-2-cyanoacrylate</td>
<td>66.7%</td>
</tr>
<tr>
<td>Fischer A et al. [12]</td>
<td>8</td>
<td>Postoperative</td>
<td>Fibrin</td>
<td>100%</td>
</tr>
<tr>
<td>Mutignani M et al. [13]</td>
<td>4</td>
<td>Postoperative</td>
<td>N-butyl-2-cyanoacrylate</td>
<td>75%</td>
</tr>
<tr>
<td>Labori KJ et al. [15]</td>
<td>4</td>
<td>Acute pancreatitis (3 cases) Postoperative (1 case)</td>
<td>N-butyl-2-cyanoacrylate</td>
<td>100%</td>
</tr>
<tr>
<td>Seewald S et al. [14]</td>
<td>2</td>
<td>Acute pancreatitis</td>
<td>N-butyl-2-cyanoacrylate</td>
<td>100%</td>
</tr>
<tr>
<td>Others [16, 17, 18, 19, 20, 21] (including the present case)</td>
<td>7</td>
<td>Acute pancreatitis (3 cases) Chronic pancreatitis (2 cases) Postoperative (2 case)</td>
<td>Fibrin (3 cases) N-butyl-2-cyanoacrylate (2 cases) Ethyl-2-cyanoacrylate (1 case) Ethylene-vinyl alcohol copolymer (1 case)</td>
<td>100%</td>
</tr>
<tr>
<td>Overall</td>
<td>37</td>
<td>Postoperative (18 cases) Acute pancreatitis (11 cases) Chronic pancreatitis (6 cases) Cancer (2 cases)</td>
<td>N-butyl-2-cyanoacrylate (24 cases) Fibrin (11 cases) Ethyl-2-cyanoacrylate (1 case) Ethylene-vinyl alcohol copolymer (1 case)</td>
<td>86.5%</td>
</tr>
</tbody>
</table>

were successfully treated with N-butyl-2-cyanoacrylate [15]. Overall, approximately 36 similar cases have been described in which endoscopic treatment with fibrin sealants (n=11) or cyanoacrylate (n=25) was used to close the fistulas (Table 1) [11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21]. The potential fears are of pancreatitis, pulmonary embolism, fever and abscess formation. However, vascular embolization is less likely when being used for fistula closure. There is no fear that glue will stick to catheter or stent as it hardens immediately. Because of underlying liver cirrhosis, any surgical intervention including tail of pancreas resection with splenectomy would have been difficult in our patient. Therefore, glue injection possibly was good way out. This modality of treatment definitely warrants larger controlled trial to determine its safety and effectiveness.

Source of support None
Conflict of interest None

References